Article
Medicine, General & Internal
Kenki Saito, Takayuki Sato, Kenji Notohara, Yasuhito Nannya, Seishi Ogawa, Yasunori Ueda
Summary: This report presents a suspected case of AML that was diagnostically challenging due to complete BMN with CLCs. However, the patient achieved complete hematologic remission with treatment similar to that for AML.
Editorial Material
Critical Care Medicine
Kota Ikari, Junichiro Tezuka, Tsubasa Matsumoto, Moeri Tsuji, Masaru Kawamura, Takuya Oda, Shigeharu Ueki
Summary: A 4-year-old boy with no asthma history presented to the emergency department with fever and wheezing, eventually diagnosed with plastic bronchitis associated with influenza A infection. Pathological examination revealed the presence of Charcot-Leyden crystals in the mucus plug, indicating a potential role of this specific crystalline substance in the formation of the mixed mucus plug.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
(2021)
Editorial Material
Cell & Tissue Engineering
Malini Gupta, Britta Will
Summary: Adaptive aberrant gene regulation is a hallmark of malignant growth and therapy resistance in acute myeloid leukemia (AML). In this study, Eagle et al. identified oncogenic enhancer-driven overexpression of selenophosphate synthetase 2 (SEPHS2) as a targeted opportunity for mitigating malignant cell growth in AML.
Review
Biochemistry & Molecular Biology
Daniela Damiani, Mario Tiribelli
Summary: The prognosis of acute myeloid leukemia (AML) is poor due to tumor cell immune escape, which weakens T-cells. Inhibiting immune checkpoints (ICs) through immune checkpoint inhibitors (ICIs) has emerged as a promising therapeutic strategy for AML. However, the results of clinical trials testing ICIs, alone or in combination with other treatments, in AML are conflicting.
Review
Biochemistry & Molecular Biology
Vijendra Singh, Mohammed Hafiz Uddin, Jeffrey A. Zonder, Asfar S. Azmi, Suresh Kumar Balasubramanian
Summary: While mechanistic studies have shed light on the molecular mechanisms of AML and led to the development of new targeted therapies, resistance remains a significant issue in AML treatment. The exploration of circRNA in AML biology and therapy resistance shows promise in providing new insights and potential solutions to managing this disease.
Review
Biochemistry & Molecular Biology
Rikako Tabata, SungGi Chi, Junichiro Yuda, Yosuke Minami
Summary: Studies have suggested the potential clinical benefits of immuno-oncology therapy against AML, including immune checkpoint inhibitors and bi-/tri-specific antibodies. CAR-T and NK cells have shown effectiveness for relapsed/refractory AML patients, and conventional chemotherapy combined with anti-PD-1/anti-CTLA4 antibodies also demonstrated certain efficacy.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Biochemistry & Molecular Biology
Fenghua Qian, Brooke E. Arner, Kathleen M. Kelly, Charyguly Annageldiyev, Arati Sharma, David F. Claxton, Robert F. Paulson, K. Sandeep Prabhu
Summary: Interleukin-4 (IL-4) plays a therapeutic role in acute myeloid leukemia (AML) by alleviating the severity of the disease. IL-4 enhances the expression of hematopoietic- PGD(2) synthase (H-PGDS) to increase the production of endogenous cyclopentenone prostaglandins (CyPGs), leading to apoptosis of leukemia-initiating cells (LICs).
Review
Oncology
Kristen J. Kurtz, Shannon E. Conneely, Madeleine O'Keefe, Katharina Wohlan, Rachel E. Rau
Summary: Acute myeloid leukemia (AML) is a genetically and phenotypically heterogeneous hematologic malignancy. Murine models of AML are indispensable research tools to better understand the mechanisms and test novel therapeutic approaches for this disease.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Hermioni L. Amonoo, Thomas W. LeBlanc, Alison R. Kavanaugh, Jason A. Webb, Lara N. Traeger, Annemarie D. Jagielo, Dagny M. Vaughn, Madeleine Elyze, Regina M. Longley, Amir T. Fathi, Gabriela S. Hobbs, Andrew M. Brunner, Nina R. O'Connor, Selina M. Luger, Jillian L. Gustin, Bhavana Bhatnagar, Nora K. Horick, Areej El-Jawahri
Summary: Patients with acute myeloid leukemia (AML) receiving intensive chemotherapy face significant PTSD symptoms related to coping, quality of life, and other factors, highlighting the importance of supportive oncology interventions.
Review
Medicine, Research & Experimental
Mengci Hu, Wenzhe Li, Youshan Zhang, Caixia Liang, Jie Tan, Ya Wang
Summary: Venetoclax, a potent BCL-2 inhibitor, has shown significant efficacy in AML treatment in preclinical and clinical trials. However, further research is needed to determine the optimal treatment strategies and identify biomarkers for predicting treatment response.
BIOMEDICINE & PHARMACOTHERAPY
(2023)
Article
Otorhinolaryngology
M. Gelardi, R. Giancaspro, M. Cassano
Summary: Nasal cytology has revealed a correlation between the severity of rhinopathies and the presence of Charcot-Leyden crystals (CLCs), which are associated with eosinophils and mast cells infiltration. Rhinopathies with abundant CLCs and a mixed eosinophilic-mast cell inflammatory infiltrate have a worse prognosis and higher risk of relapse.
AMERICAN JOURNAL OF OTOLARYNGOLOGY
(2023)
Review
Immunology
Thomas Menter, Alexandar Tzankov
Summary: This review examines the complex relationship between leukemic cells and the tumor microenvironment in AML, focusing on niche cells and T-cell subsets, and explores potential therapeutic strategies for manipulating the tumor microenvironment.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Multidisciplinary Sciences
Meike Farber, Yiyang Chen, Lucas Arnold, Michael Moellmann, Eva Boog-Whiteside, Yu-An Lin, H. Christian Reinhardt, Ulrich Duehrsen, Maher Hanoun
Summary: Targeting the interaction between leukemic cells and the microenvironment by inhibiting CD38 has the potential to enhance therapeutic efficacy in AML. However, while the anti-CD38 antibody daratumumab showed significant cytostatic efficacy in an in vitro model, it ultimately lacked robust anti-leukemic effects in vivo in a xenograft transplantation model.
SCIENTIFIC REPORTS
(2021)
Article
Medicine, General & Internal
Pau Montesinos, Christian Recher, Susana Vives, Ewa Zarzycka, Jianxiang Wang, Giambattista Bertani, Michael Heuser, Rodrigo T. Calado, Andre C. Schuh, Su-Peng Yeh, Scott R. Daigle, Jianan Hui, Shuchi S. Pandya, Diego A. Gianolio, Stephane de Botton, Hartmut Dohner
Summary: This study demonstrated that the combination therapy of oral ivosidenib and azacitidine showed better event-free survival and longer overall survival in patients with newly diagnosed IDH1-mutated acute myeloid leukemia.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Oncology
Yifan Zhai, Qiuqiong Tang, Douglas D. Fang, Jing Deng, Kaixiang Zhang, Qixin Wang, Yan Yin, Chengcheng Fu, Sheng -Li Xue, Na Li, Feng Zhou, Dajun Yang
Summary: This study aimed to determine if novel anticancer agents targeting BCL-2 and MDM2 could overcome venetoclax resistance. The combination of lisaftoclax and alrizomadlin exhibited synergistic antitumor effects and overcame venetoclax resistance mediated by various mechanisms, including BCL-2 mutations. These findings provide a theoretical basis for the clinical application of this treatment combination in patients with resistant diseases.
CLINICAL CANCER RESEARCH
(2023)
